Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
January 7, 2012
Protein crystallization for structure-based drug design
Isaac D Hoffman
Bioorganic & Medicinal Chemistry Letters
|
December 13, 2006
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors
Leslie W Tari, Isaac D Hoffman, Daniel C Bensen, et al.
Current Chemical Genomics
|
June 18, 2010
Mechanism of Inhibition of Novel Tryptophan Hydroxylase Inhibitors Revealed by Co-crystal Structures and Kinetic Analysis
Giovanni Cianchetta, Terry Stouch, Wangsheng Yu, et al.
Journal of Medicinal Chemistry
|
July 13, 2017
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
Tomohiro Okawa, Yoshio Aramaki, Mitsuo Yamamoto, et al.
Journal of Medicinal Chemistry
|
September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
Robert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry
|
August 11, 2017
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders
Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, et al.
Journal of Medicinal Chemistry
|
March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations
Robert L Hudkins, Eric Allen, Samhita Iyer, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 15, 2016
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, et al.
Journal of Medicinal Chemistry
|
March 7, 2018
Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist
Mitsunori Kono, Atsuko Ochida, Tsuneo Oda, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2019
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode
Jun Fujimoto, Osamu Kurasawa, Terufumi Takagi, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Methods in Molecular Biology (Clifton, N.J.)
|
January 7, 2012
Protein crystallization for structure-based drug design
Isaac D Hoffman
Bioorganic & Medicinal Chemistry Letters
|
December 13, 2006
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors
Leslie W Tari, Isaac D Hoffman, Daniel C Bensen, et al.
Current Chemical Genomics
|
June 18, 2010
Mechanism of Inhibition of Novel Tryptophan Hydroxylase Inhibitors Revealed by Co-crystal Structures and Kinetic Analysis
Giovanni Cianchetta, Terry Stouch, Wangsheng Yu, et al.
Journal of Medicinal Chemistry
|
July 13, 2017
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
Tomohiro Okawa, Yoshio Aramaki, Mitsuo Yamamoto, et al.
Journal of Medicinal Chemistry
|
September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
Robert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry
|
August 11, 2017
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders
Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, et al.
Journal of Medicinal Chemistry
|
March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations
Robert L Hudkins, Eric Allen, Samhita Iyer, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 15, 2016
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, et al.
Journal of Medicinal Chemistry
|
March 7, 2018
Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist
Mitsunori Kono, Atsuko Ochida, Tsuneo Oda, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2019
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode
Jun Fujimoto, Osamu Kurasawa, Terufumi Takagi, et al.
Page
of 1